Format

Send to

Choose Destination
Channels (Austin). 2019 Dec;13(1):1-16. doi: 10.1080/19336950.2018.1547611.

"TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure".

Author information

1
a Laboratory of Experimental Medicine, John A. Burns School of Medicine , University of Hawaii , Honolulu , HI 96813 USA.
2
i Laboratory of Molecular Biology, Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University , Nishikyo-ku, Kyoto, 615-8510, Japan.
3
g GB Sciences Inc., 3550 W Teco Ave, Las Vegas, NV 89118 USA.
4
b Department of Cell and Molecular Biology, John A. Burns School of Medicine , University of Hawaii , Honolulu , HI 96813 USA.
5
c Queen's Medical Center, Punchbowl Street , Honolulu, HI, USA.
6
d Division of Natural Sciences and Mathematics, Chaminade University , Honolulu, HI USA.
7
h Department of Pathophysiology Faculty of Medicine, Oita University 1-1 Idaigaoka, Hasama, Yufu, Oita 879-5593, Japan.
8
e Department of Molecular Biosciences and Bioengineering, University of Hawaii , Honolulu, HI 96822 USA.
9
f Diabetes Research Center, John A. Burns School of Medicine, University of Hawaii , Honolulu, HI 96813 USA.

Abstract

Activation of the atrial natriuretic signaling pathway is intrinsic to the pathological responses associated with a range of cardiovascular diseases that stress the heart, especially those involved in sustained cardiac pressure overload which induces hypertrophy and the pathological remodeling that frequently leads to heart failure. We identify transient receptor potential cation channel, subfamily V, member 1, as a regulated molecular component, and therapeutic target of this signaling system. Data show that TRPV1 is a physical component of the natriuretic peptide A, cGMP, PKG signaling complex, interacting with the Natriuretic Peptide Receptor 1 (NPR1), and upon binding its ligand, Natriuretic Peptide A (NPPA, ANP) TRPV1 activation is subsequently suppressed through production of cGMP and PKG mediated phosphorylation of the TRPV1 channel. Further, inhibition of TRPV1, with orally delivered drugs, suppresses chamber and myocyte hypertrophy, and can longitudinally improve in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction, reversing pre-established hypertrophy induced by pressure load while restoring chamber function. TRPV1 is a physical and regulated component of the natriuretic peptide signaling system, and TRPV1 inhibition may provide a new treatment strategy for treating, and reversing the loss of function associated with cardiac hypertrophy and heart failure.

KEYWORDS:

Atrial natriuretic peptide (ANP); heart failure; hypertrophy; ion channel; ionotrophic cannabinoid receptor; member 1 (TRPV1); sildenafil; subfamily V; therapeutic; transient receptor potential cation channel

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center